Propanc Biopharma highlights potential of lead proenzyme therapy

Propanc Biopharma (PPCB) highlighted the potential of its lead proenzyme therapy, PRP, as a novel approach that could compete with existing approved therapies for solid tumors, particularly in areas of high unmet need such as pancreatic cancer. Preclinical studies have demonstrated significant effects, including over 85% tumor growth inhibition in models and enhanced chemosensitivity, suggesting PRP could improve outcomes when used alongside or as an alternative to standard treatments. “We are excited about PRP’s potential to transform cancer care by targeting the underlying mechanisms of metastasis with a mechanism that could offer meaningful advantages over existing therapies,” said Mr James Nathanielsz, Propanc’s Chief Executive Officer. “As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.”